Esperion Logo (primary).png
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
August 02, 2022 07:00 ET | Esperion Therapeutics, Inc.
– Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 – – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and...
Esperion Logo (primary).png
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
July 25, 2022 15:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the establishment of its Scientific Advisory Board (SAB). The inaugural members of the Esperion SAB...
Esperion Logo (primary).png
Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
June 03, 2022 12:30 ET | Esperion Therapeutics, Inc.
– Less than 1 in 10 were on any non-statin lipid lowering therapy – – Findings were shared at the National Lipid Association Scientific Sessions – ANN ARBOR, Mich., June 03, 2022 (GLOBE...
Esperion Logo (primary).png
Esperion to Participate in the 2022 Jefferies Global Healthcare Conference
June 02, 2022 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming 2022 Jefferies...
Esperion Logo (primary).png
Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors
June 01, 2022 16:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperion’s Board of Directors. Mr. Carroll will...
Esperion Logo (primary).png
Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions
May 31, 2022 08:00 ET | Esperion Therapeutics, Inc.
– Highlight of accepted abstracts includes new real-world data on lipid-lowering therapy usage, submitted in partnership with UT Southwestern – – Accepted abstracts showcase breadth of Esperion’s...
Esperion Logo (primary).png
Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference
May 17, 2022 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will participate in a fireside chat at the...
Esperion Logo (primary).png
Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
May 03, 2022 07:00 ET | Esperion Therapeutics, Inc.
– Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation– – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew...
Esperion Logo (primary).png
Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology
May 02, 2022 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also...
Esperion Logo (primary).png
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 29, 2022 17:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on April 28, 2022, the Compensation Committee of Esperion’s Board of Directors granted 14 new...